매사추세츠의 폐암 임상 시험
폐암 관련 연구 76개가 매사추세츠 내 여러 지역에서 참여자를 모집하고 있습니다.
매사추세츠의 도시
- Boston연구 63개
- Worcester연구 11개
- Somerville연구 7개
- Springfield연구 5개
- Lynn연구 3개
- Newton연구 3개
- Lawrence연구 3개
- Quincy연구 3개
공식 연구 텍스트(영어)
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
- Reliant Medical Group Inc, Worcester
피험자 모집 중3상
18세 ~ 100세 · 모든 성별 · 2026. 11. 13. 업데이트됨 · NCT05920356A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
- Dana-Farber Cancer Institute, Boston
피험자 모집 중2/3상
18세 이상 · 모든 성별 · 2026. 11. 13. 업데이트됨 · NCT07063745EQUAL: EGFR ctDNA QUantative Assessment for Lung Cancer Screening in Asian and Latinx Populations
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
- Massachusetts General Hospital, Boston
- 외 3개
피험자 모집 중건강한 지원자 환영
40세 ~ 80세 · 모든 성별 · 2026. 11. 13. 업데이트됨 · NCT06716580Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy With or Without Amivantamab for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
- Dana-Farber Cancer Institute, Boston
피험자 모집 중2/3상
18세 이상 · 모든 성별 · 2026. 11. 12. 업데이트됨 · NCT07100080This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
- Southcoast Centers for Cancer Care, Fairhaven
- Southcoast Centers for Cancer Care, Fall River
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 11. 12. 업데이트됨 · NCT06758401Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- Beverly Hospital, Beverly
- Lahey Clinic, Burlington
- Addison Gilbert Hospital, Gloucester
- 외 3개
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 11. 12. 업데이트됨 · NCT06498635Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Beverly Hospital, Beverly
- Boston Medical Center, Boston
- Beth Israel Deaconess Medical Center, Boston
- 외 8개
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 11. 12. 업데이트됨 · NCT04267848Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
- Tufts Medical Center, Boston
- Dana-Farber Cancer Institute at Boston Medical Center - Brighton, Brighton
- Dana-Farber Cancer Institute at Foxborough, Foxborough
- 외 3개
피험자 모집 중3상
70세 이상 · 모든 성별 · 2026. 11. 12. 업데이트됨 · NCT06096844A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
- Mass General Brigham Cancer Institute at Massachusetts General Hospital, Boston
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 11. 12. 업데이트됨 · NCT07458347A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
- Massachusetts General Hospital, Boston
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 11. 10. 업데이트됨 · NCT07020221Health Opportunities and Promoters of Equitable Screening for Lung Cancer
- Massachusetts General Hospital, Boston
피험자 모집 중관찰 연구
50세 ~ 80세 · 모든 성별 · 2026. 11. 9. 업데이트됨 · NCT05784922Multi-site Trial of a Brief Behavioral Intervention for Dyspnea in Patients With Advanced Lung Cancer
- Massachusetts General Hospital, Boston
피험자 모집 중
18세 이상 · 모든 성별 · 2026. 11. 5. 업데이트됨 · NCT06791057A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Massachusetts General Hospital, Boston
- University of Massachusetts Memorial Medical Center, Worcester
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 11. 5. 업데이트됨 · NCT06793215Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
- UMass Memorial Medical Center - University Campus, Worcester
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 11. 4. 업데이트됨 · NCT04181060A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
- Local Institution - 0124, Boston
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 11. 4. 업데이트됨 · NCT07492680Distance-Based Exercise to Preserve Function and Prevent Disability
- Dana-Farber Cancer Institute, Boston
피험자 모집 중
18세 이상 · 모든 성별 · 2026. 11. 4. 업데이트됨 · NCT07059884A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Boston Medical Center, Boston
- Lahey Hospital & Medical Center, Burlington
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 11. 4. 업데이트됨 · NCT06119581Preliminary Efficacy of Different Exercise Training During Immunotherapy in Patients With Lung Cancer: The ENHANCE Trial
- Dana-Farber Cancer Institute, Boston
피험자 모집 중
18세 이상 · 모든 성별 · 2026. 10. 26. 업데이트됨 · NCT06026111A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
- Research Site, Boston
- Research Site, Boston
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 10. 26. 업데이트됨 · NCT06835569Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy
- VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA, Boston
피험자 모집 중
18세 이상 · 모든 성별 · 2026. 10. 23. 업데이트됨 · NCT02984761Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 10. 23. 업데이트됨 · NCT06922591Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
- Research Site, Boston
피험자 모집 중2상
18세 ~ 95세 · 모든 성별 · 2026. 10. 21. 업데이트됨 · NCT05061550Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
- Dana Farber Cancer Institute, Boston
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 10. 21. 업데이트됨 · NCT06810544A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
- Dana-Farber Cancer Institute, Boston
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 10. 19. 업데이트됨 · NCT06244771Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
- Dana Farber Cancer Institute, Boston
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 10. 19. 업데이트됨 · NCT06162221AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
- Avenzo Therapeutics Recruiting Site, Boston
피험자 모집 중1/2상
18세 ~ 75세 · 모든 성별 · 2026. 10. 16. 업데이트됨 · NCT07038343Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
- Beth Israel Lahey Health - Lahey Hospital & Medical Center (LHMC), Lahey Clinic Medical Center, Burlington
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 10. 14. 업데이트됨 · NCT06712355Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
- Dana-Farber Cancer Institute, Boston
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 10. 13. 업데이트됨 · NCT05786924Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- Dana Farber Cancer Institute, Boston
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 10. 13. 업데이트됨 · NCT06293898Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
- Lahey Clinic, Burlington
- UMass Memorial Medical Center - University Campus, Worcester
피험자 모집 중2상
18 Minutes · 모든 성별 · 2026. 10. 9. 업데이트됨 · NCT06031688Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
- Beverly Hospital, Beverly
- Lahey Clinic, Burlington
- Addison Gilbert Hospital, Gloucester
- 외 3개
피험자 모집 중2/3상
18세 이상 · 모든 성별 · 2026. 10. 9. 업데이트됨 · NCT06616584DNA Analysis of Blood and Tissue From Patients With Lung Cancer
- Massachusetts General Hospital, Boston
- Harvard School of Public Health, Boston
피험자 모집 중관찰 연구건강한 지원자 환영
18세 ~ 120세 · 모든 성별 · 2026. 10. 7. 업데이트됨 · NCT00471978Boston Lung Cancer Study (Molecular and Genetic Analysis of Lung Cancer)
- Massachusetts General Hospital, Boston
피험자 모집 중관찰 연구
18세 이상 · 모든 성별 · 2026. 10. 7. 업데이트됨 · NCT03029325The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
피험자 모집 중1/2상
12세 이상 · 모든 성별 · 2026. 10. 2. 업데이트됨 · NCT04585750Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Insitute, Boston
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 10. 1. 업데이트됨 · NCT06625775Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
- Dana-Farber Cancer Institute, Boston
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 30. 업데이트됨 · NCT06765109A Study of PHN-012 in Patients With Advanced Solid Tumors
- PHN-012-001 Site, Boston
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 9. 29. 업데이트됨 · NCT07127874A Registry for People With Lung Cancer
- Massachusetts General Hospital Cancer Center (Data Collection Only), Boston
- Brigham and Women's Hospital (Data Collection Only), Boston
피험자 모집 중관찰 연구
18세 이상 · 모든 성별 · 2026. 9. 24. 업데이트됨 · NCT06424327Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- Dana Farber Cancer Institute, Boston
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 9. 22. 업데이트됨 · NCT06128551A Community Health Intervention to Improve Lung Cancer Screening Uptake in Community Health Centers
- Baystate Health, Springfield
피험자 모집 중건강한 지원자 환영
50세 ~ 80세 · 모든 성별 · 2026. 9. 22. 업데이트됨 · NCT07168629ClinicalTrials.gov 출처, 2026. 11. 15. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.